secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rallybio Corp (RLYB)
CIK:        0001739410
Form:       8-K
Filed at:   2026-03-02T23:59:59+00:00
Accession:  0001193125-26-084444
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.01, 3.02, 5.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rallybio agrees to reverse merger with Candid; Rallybio holders get ~3.65% of combined firm
--------------------------------------------------------------------------------

- Rallybio pre-merger holders expected to own ~3.65% of combined company; Candid holders ~57.55%; financing investors ~38.80% (based on $505.5M raise).
- Concurrent $505.5M private placement from accredited investors, shares convert to Rallybio common at closing.
- Post-merger CEO will be Ken Song, current Candid Chairman/President/CEO; current Rallybio executives to resign.
- Rallybio regained Nasdaq $1.00 bid compliance after 1-for-8 reverse stock split effective Feb 6, 2026.
- Rallybio stockholders must approve share issuance (>20%), reverse split, name change to 'Candid Therapeutics, Inc.'

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739410/000119312526084444/0001193125-26-084444-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739410/000119312526084444/d108429d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-084444

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer